Buruli ulcer — a disfiguring, often treatment-resistant skin infection caused by Mycobacterium ulcerans — has puzzled epidemiologists for decades partly because its transmission route remains incompletely understood. A randomized controlled field trial in Melbourne now provides some of the strongest causal evidence yet that a specific mosquito species is a meaningful vector, and that suppressing that vector translates directly into fewer human infections.
The trial deployed 100 autodissemination stations per geographic zone across six intervention areas in an endemic Melbourne suburb over eight weeks in early 2024, with six matched control zones receiving no intervention. Each station combined two biocontrol agents: pyriproxyfen, an insect growth regulator that disrupts larval development, and Beauveria bassiana, an entomopathogenic fungus that kills adult mosquitoes by penetrating the cuticle. The autodissemination mechanism works by coating visiting mosquitoes with the larvicide, which they then carry to breeding sites — effectively turning the insects against their own offspring. Mosquito egg counts fell by an average of 70% across intervention zones (P = 0.0076). Adjusting for the 4.8-month mean incubation period of M. ulcerans, Buruli ulcer notifications dropped by 83% in treatment zones compared to controls, with a striking incidence rate ratio of 0.167 and an R² of 0.85 between mosquito suppression and disease reduction.
This finding carries meaningful weight for several reasons. The controlled design with geographic randomization sharply limits confounding, a chronic weakness of observational vector-control studies. The biological plausibility is reinforced by the tight temporal alignment between the intervention effect and the lagged disease signal — and the absence of a comparable signal in the same periods the year before or after, when no stations were deployed. That said, the Buruli ulcer arm was an ad hoc analysis on small case counts (seven total), meaning confidence intervals are wide and the P-value just crosses the 0.05 threshold. This is confirmatory but not definitive on the disease endpoint. The mosquito suppression result, however, is robust. If replicated at scale, this approach could offer a practical, insecticide-lite tool for endemic communities across sub-Saharan Africa and coastal Australia where Buruli ulcer burden remains high.